Status:
RECRUITING
Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)
Lead Sponsor:
Henan Cancer Hospital
Conditions:
Esophageal Squamous Cell Carcinoma
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
Multimodal treatment combining surgery with chemotherapy and/or radiotherapy is necessary to improve the chances of survival in patients with locally advanced thoracic esophageal cancer. However, ther...
Eligibility Criteria
Inclusion
- cT2-T4aN+M0 or cT3-4aN0M0 (8th TNM staging system) thoracic esophageal squamous cell carcinoma
- No metastatic cervical lymph node
- No anti-cancer treatment
- No contraindication for esophagectomy
- No contraindication for chemotherapy or chemoradiation therapy
- PS score 0-1
- Written consent is obtained
Exclusion
- Previous cancer treatment history
- Concurrent cancer disease in other site
- Tumor length ≥8cm
- Tumor width ≥5cm
- Need continuous steroid treatment
- Cardiac infarction in 6 months
- Psychotic patient
- Can not achieve R0 resection
- Gastric tube can not be used for reconstruction after esophagectomy
- Pregnant woman
Key Trial Info
Start Date :
October 22 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 21 2028
Estimated Enrollment :
456 Patients enrolled
Trial Details
Trial ID
NCT04138212
Start Date
October 22 2019
End Date
December 21 2028
Last Update
August 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Henan Cancer Hospital
Zhengzhou, Henan, China, 450008